656 related articles for article (PubMed ID: 21540239)
1. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
[TBL] [Abstract][Full Text] [Related]
2. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia.
Xerri L; Chetaille B; Serriari N; Attias C; Guillaume Y; Arnoulet C; Olive D
Hum Pathol; 2008 Jul; 39(7):1050-8. PubMed ID: 18479731
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of tumor necrosis factor-alpha gene by Epstein-Barr virus and activation of macrophages in Epstein-Barr virus-infected T cells in the pathogenesis of hemophagocytic syndrome.
Lay JD; Tsao CJ; Chen JY; Kadin ME; Su IJ
J Clin Invest; 1997 Oct; 100(8):1969-79. PubMed ID: 9329960
[TBL] [Abstract][Full Text] [Related]
4. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens.
Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N
Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005
[TBL] [Abstract][Full Text] [Related]
5. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.
Sugita S; Usui Y; Horie S; Futagami Y; Yamada Y; Ma J; Kezuka T; Hamada H; Usui T; Mochizuki M; Yamagami S
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):263-72. PubMed ID: 18775867
[TBL] [Abstract][Full Text] [Related]
6. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
[TBL] [Abstract][Full Text] [Related]
7. Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions.
Nagamatsu T; Schust DJ; Sugimoto J; Barrier BF
Hum Reprod; 2009 Dec; 24(12):3160-71. PubMed ID: 19729380
[TBL] [Abstract][Full Text] [Related]
8. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation.
Norde WJ; Maas F; Hobo W; Korman A; Quigley M; Kester MG; Hebeda K; Falkenburg JH; Schaap N; de Witte TM; van der Voort R; Dolstra H
Cancer Res; 2011 Aug; 71(15):5111-22. PubMed ID: 21659460
[TBL] [Abstract][Full Text] [Related]
9. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis.
Lee J; Zhuang Y; Wei X; Shang F; Wang J; Zhang Y; Liu X; Yang Y; Liu L; Zheng Q
J Mol Cell Cardiol; 2009 Feb; 46(2):169-76. PubMed ID: 19056397
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis.
Ding H; Wu X; Gao W
Clin Immunol; 2005 May; 115(2):184-91. PubMed ID: 15885642
[TBL] [Abstract][Full Text] [Related]
11. Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Imai C; Kitanaka A; Takihara Y; Kimura A
J Immunother; 2009 Sep; 32(7):737-43. PubMed ID: 19561535
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis.
Mühlbauer M; Fleck M; Schütz C; Weiss T; Froh M; Blank C; Schölmerich J; Hellerbrand C
J Hepatol; 2006 Oct; 45(4):520-8. PubMed ID: 16876901
[TBL] [Abstract][Full Text] [Related]
13. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
14. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
15. T-cell suppression by programmed cell death 1 ligand 1 on retinal pigment epithelium during inflammatory conditions.
Sugita S; Usui Y; Horie S; Futagami Y; Aburatani H; Okazaki T; Honjo T; Takeuchi M; Mochizuki M
Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2862-70. PubMed ID: 19182257
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression on tolerogenic APCs is controlled by STAT-3.
Wölfle SJ; Strebovsky J; Bartz H; Sähr A; Arnold C; Kaiser C; Dalpke AH; Heeg K
Eur J Immunol; 2011 Feb; 41(2):413-24. PubMed ID: 21268011
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
Waeckerle-Men Y; Starke A; Wüthrich RP
Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of T and B lymphocytes by PD-1 and SOCS-1 signaling in hepatitis C virus-associated non-Hodgkin's lymphoma.
Yao ZQ; Ni L; Zhang Y; Ma CJ; Zhang CL; Dong ZP; Frazier AD; Wu XY; Thayer P; Borthwick T; Chen XY; Moorman JP
Immunol Invest; 2011; 40(3):243-64. PubMed ID: 21291295
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
Miles RR; Cairo MS; Satwani P; Zwick DL; Lones MA; Sposto R; Abromovitch M; Tripp S; Angiolillo AL; Roman E; Davenport V; Perkins SL
Br J Haematol; 2007 Aug; 138(4):506-12. PubMed ID: 17659054
[TBL] [Abstract][Full Text] [Related]
20. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma.
Willenbrock K; Küppers R; Renné C; Brune V; Eckerle S; Weidmann E; Bräuninger A; Hansmann ML
Haematologica; 2006 May; 91(5):596-604. PubMed ID: 16670065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
